Chronic Hepatitis B Infection Amongst PrEP Users Enrolled in a Population-Based Program in British Columbia, Canada
Keyword(s):
Hbv Dna
◽
Abstract Initiation of HIV Pre-Exposure Prophylaxis (PrEP) medications will also treat hepatitis B infection (HBV). The prevalence of chronic HBV was 0.86% (n=41/4,760) among enrollees in a provincial PrEP program in British Columbia, Canada. Overall, 46.3% lacked follow-up HBV DNA monitoring, underscoring the need for HBV-related education for PrEP prescribers.